(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s non-prostate cancer session included a presentation by Dr. Yann Vano discussing the CABIR study of patients receiving cabozantinib-nivolumab versus nivolumab-cabozantinib after receiving a prior VEGFR TKI for metastatic clear cell RCC. Nivolumab and cabozantinib are two approved agents after a prior TKI in metastatic RCC patients. However, the optimal sequence, cabozantinib-nivolumab or nivolumab-cabozantinib, is still unknown. The superiority of cabozantinib over everolimus in patients with prior anti-PD-1 (HR 0.22, 95% CI 0.07-0.65) in the METEOR trial suggests a sensitizing role of nivolumab.1 At the 2021 ESMO congress, Dr. Vano and colleagues presented results of the CABIR study to identify the optimal sequence between cabozantinib-nivolumab and nivolumab-cabozantinib after one prior TKI.